In vitro screening methods to assess the potential of in vivo precipitation of injectable formulations upon intravenous administration

PDA Journal of Pharmaceutical Science and Technology

Volumn 65, Issue 1, 2011, Pages 71-80

  Sheth, Agam R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dynamic model; Formulation; In vivo; Injectible; Intravenous; Phlebitis; Precipitation; Screening; Solution; Static dilution

Indexed keywords

AMIODARONE; CIPROFLOXACIN; DOBUTAMINE; NAFCILLIN; PHENYTOIN;

AQUEOUS SOLUTION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DILUTION; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MICROSCOPY; NONHUMAN; PKA; PRECIPITATION; ANIMAL; INDICATOR DILUTION CURVE; INJECTION; MEDICINAL CHEMISTRY; SOLUBILITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; IN VITRO TECHNIQUES; INDICATOR DILUTION TECHNIQUES; INFUSIONS, INTRAVENOUS; INJECTIONS; INJECTIONS, INTRAVENOUS; SOLUBILITY;

EID: 80053041246     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yalkowski, S. H.; Roseman, T. J. Chapter 3. Solubilization of Drugs by Cosolvents. In Techniques of Solubilization of Drugs; Yalkowski, S. H., Ed.; Marcel Dekker: New York, 1981.
2. Schroeder, H. G.; DeLuca, P. P. A study on the in vivo precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenter. Drug Assoc. 1974, 28 (1), 1-14.
3. Yalkowski, S. H.; Valvani, S. C.; Johnson, B. W. In vitro method for detecting precipitation of parenteral formulations after injection. J. Pharm. Sci. 1983, 72 (9), 1014 -1017.
4. Repta, A. J. Chapter 4. Alteration of Apparent Solubility through Complexation. In Techniques of Solubilization of Drugs; Yalkowski, S. H., Ed.; Marcel Dekker: New York, 1981.
5. Davio, S. R.; Mc Shane, M. M.; Kakuk, T. J.; Zaya, R. M.; Cole, S L. Precipitation of the rennin inhibitor ditekiren upon IV infusion; in vitro studies and their relationship to in vivo precipitation in the Cynomolgus monkey. Pharm. Res. 1991, 8 (1), 80-83.
6. Greenfield, J. C.; Loux, S. J.; Sood, V. K.; Jenkins, K. M.; Davio, S. M. In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel rennin inhibitor pseudopeptide. Pharm. Res. 1991, 8 (4), 475- 479.
7. Cox, J. W.; Sage, G. P.; Wynalda, M. A.; Ulrich, R. G.; Larson, P. G.; Su, C. C. Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J. Pharm. Sci. 1991, 80 (4), 371-375.
8. Myrdal, P. B.; Simamora, P.; Surakitbanharn, Y.; Yalkowski, S. H. Studies in phlebitis. VII: In vitro and in vivo evaluation of pH solubilized levenmopamil. J. Pharm. Sci. 1995, 84 (7), 849 - 852.
9. Simamora, P.; Pinsuwan, S.; Surakitbanham, Y.; Yalkowski, S. H. Studies in phlebitis. VIII: Evaluations of pH solubilized intravenous dexverapamil formulations. PDA J. Pharm. Sci. Technol. 1996, 50 (2), 123-128.
10. Johnson, J. L. H.; Yalkowsky, S. H. Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength. AAPS PharmSciTech 2006, 7 (1), E1-E5.
11. Jencks, W. P. Catalysis in Chemistry and Enzymology; Mc-Graw Hill: New York, 1969; pp 358-392.
12. Yalkowski, S. H.; Krzyzaniak, J. F.; Ward, G. H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7), 787-796. (Pubitemid 28319406)
13. Portmann, G. A.; Simmons, D. M. Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. J. Pharm. Biomed. Anal. 1995, 13 (9), 1189 -1193.
14. Johnson, J. L. H.; He, Y.; Yalkowsky, S. H. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J. Pharm. Sci. 2003, 92 (8), 1574 -1581.
15. Ward, G. H.; Yalkowsky, S. H. The role of effective concentration in interpreting hemolysis data. J. Parenter. Sci. Technol. 1992, 46 (5), 161-162.
16. Rubino, J. T.; Nellore, R.; Parmar, B. Dynamic compatibility testing of DMP 840, and experimental antitumor agent. PDA J. Pharm. Sci. Technol. 1997, 51 (3), 130 -136.
17. Olson, W. P.; Faith, M. R. Human serum albumin as a cosolvent for parenteral drugs. J. Parenter. Sci. Technol. 1988, 42 (3), 82- 85.
18. Rodriguez-Hornedo, N. Crystallization and the properties of crystals. In Encyclopedia of Pharmaceutical Technology, V3; Swarbrick, J., Boylan, J. C., Eds.; Marcel Dekker: New York, 1992; pp 399 - 434.
19. Ziller, K. H.; Rupprecht, H. H. Control of crystal growth in drug suspensions. Part 2. Influence of polymers on dissolution and crystallization during temperature cycling. Pharm. Ind. 1990, 52, 1017-1022. (Pubitemid 20330148)
20. Bittner, B.; Mountfield, R. J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Devel. 2002, 5 (1), 59 -71.
21. Alvarez-Nunez, F. A.; Yalkowsky, S. H. Buffer capacity and precipitation control of pH solubilized phenytoin formulations. Int. J. Pharm. 1999, 185 (1), 45- 49.
22. Li, P.; Rao, V.; Tabibi, S. E.; Yalkowsky, S. H. Evaluation of in vitro precipitation methods. J. Pharm. Sci. 1998, 87 (2), 196 -199.
23. Narazaki, R.; Sanghvi, R.; Yalkowsky, S. H. Estimation of drug precipitation upon dilution of pH-controlled formulations. Mol. Pharm. 2007, 4 (4), 550 -555.